TCGA-BL-A13J-01A-11R-A277-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.660972405
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- MITOTIC_SPINDLE+0.430
- UV_RESPONSE_DN+0.420
- HYPOXIA+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.290
- TGF_BETA_SIGNALING+0.270
- G2M_CHECKPOINT+0.240
- MTORC1_SIGNALING+0.230
- HEME_METABOLISM+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- INTERFERON_ALPHA_RESPONSE-0.390
- PANCREAS_BETA_CELLS-0.340
- KRAS_SIGNALING_DN-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- ALLOGRAFT_REJECTION-0.230
- COAGULATION-0.230
- OXIDATIVE_PHOSPHORYLATION-0.230
- XENOBIOTIC_METABOLISM-0.230
- INTERFERON_GAMMA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BL-A13J-01A-11R-A10U-07 | — | — | 0.794 |
| 2 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.719 |
| 3 | MDT-AP-3299 | Med | Medulloblastoma | 0.716 |
| 4 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.714 |
| 5 | TCGA-91-6829-01A-21R-1858-07 | — | cohortA1 | 0.711 |
| 6 | TCGA-A7-A13D-01A-13R-A277-07 | — | E | 0.703 |
| 7 | TCGA-E9-A226-01A-21R-A157-07 | — | B | 0.702 |
| 8 | MNG502 | — | — | 0.701 |
| 9 | MNG1062 | — | — | 0.701 |
| 10 | MNG1025 | — | — | 0.699 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |